Regeneron (REGN) PT Trimmed to $380 at Cowen

Cowen trimmed its price target on Regeneron Pharma (NASDAQ: REGN) to $380.00 (from $400.00) and maintained a Market Perform rating.

Analyst Phil Nadeau commented, "This evening REGN announced Q4:16 Eylea U.S. sales of 858MM just below consensus ( 875MM). SNY s Le Trait fill and finish facility was recently reclassified as acceptable by FDA seemingly clearing the way for Dupixent s approval around its March PDUFA. We have removed U.S. Praluent sales from our model after Mid:17 reducing our price target from 400 to 380. We remain at Market Perform."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $355.06 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen